Logo of Imricor Medical Systems (ASX:IMR)Latest Imricor Medical Systems (ASX:IMR) News

Page 1
Page 1 of 5

Market Wrap - Week 46 (9 Nov -> 13 Nov) 2026

Takeover bids and major project deals drove the week, while distressed companies faced suspensions, cash shortages and tough funding choices.
Resources remained active, but investors punished weak earnings, delayed projects and uncertain access to money.
Logan Eniac
14 Nov 2026

Healthcare Wrap - Week 46 (9 Nov -> 13 Nov) 2026

EBR’s WiSE rollout slowed sharply as debt worries hit the stock, while Biome gained on a planned China launch.
Across aged care and healthcare technology, investors weighed stronger revenue against cash needs, trial delays and regulatory hurdles.
Logan Eniac
14 Nov 2026

Imricor’s US launch gets real with two NorthStar hospital customers

Imricor Medical Systems (ASX:IMR) has moved from regulatory preparation into US commercial deployment, signing its first two NorthStar hospital customers within weeks of launch. The milestone comes with sharply higher quarterly revenue, a fresh Philips pathway and a still-heavy cash burn.
Victor Sage
13 Nov 2026

Healthcare Wrap - Week 41 (5 Oct -> 9 Oct) 2026

Cynata led the week after launching a small capital raising, while Vitasora and Neurizon posted strong gains despite very different risks. Across healthcare, trial progress and regulator feedback competed with cash warnings and weaker share prices after trading gaps.
Logan Eniac
10 Oct 2026

Imricor clears major FDA PMA review with one software deficiency

Imricor has completed FDA review of the largest module in its US Premarket Approval application, with no deficiencies found in its ablation catheter or irrigation tubing. One operating-system issue remains for the RF-5000 System, but the company says it has already updated the software and is preparing its response.
Victor Sage
8 Oct 2026

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.
Logan Eniac
5 Sept 2026

FDA Closes Manufacturing Module in Imricor’s PMA Submission

Imricor Medical Systems has reached a crucial milestone as the FDA accepts and closes the manufacturing module of its Premarket Approval submission, advancing its MR-guided electrophysiology devices closer to US market entry.
Ada Torres
3 Sept 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

Imricor and Philips Unveil Commercial iMR Lab Solution for Cardiac Interventions

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.
Ada Torres
28 Aug 2026

Market Wrap - Week 33 (10 Aug -> 14 Aug) 2026

Small explorers led the ASX week, with Lachlan Star, EcoGraf and Basin Energy recording the biggest gains on new drilling, offtake and exploration news.
Takeovers, capital raisings and strong company results also drew attention, although several large stocks fell despite reporting better earnings.
Logan Eniac
15 Aug 2026

Healthcare Wrap - Week 33 (10 Aug -> 14 Aug) 2026

Healthcare shares delivered mixed results as Percheron surged on a leadership change, while ResMed gained on stronger sales and portfolio changes.
Biotech funding, medical-device expansion and new software contracts shaped the week, but several small-cap gaps quickly lost ground.
Logan Eniac
15 Aug 2026

Imricor Accelerates US Launch with Two Leading Pediatric Hospitals Securing NorthStar

Imricor Medical Systems has ignited its US commercial operations with rapid adoption by top pediatric hospitals, buoyed by FDA pediatric clearances and clinical trial progress.
Ada Torres
10 Aug 2026